InflaRx

97 articles about InflaRx

• InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa

  11/8/2018

  Trial Results Anticipated First Half 2019

• InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing

  10/30/2018

  InflaRx N.V. today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).

• InflaRx N.V. Announces Appointment of Jens Holstein  to Board of Directors

  9/21/2018

  InflaRx N.V. announced today that Jens Holstein has been appointed as a new board member of InflaRx, serving as Non-Executive Director.

• InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1

  8/28/2018

  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, will host an R&D Day on Hidradenitis Suppurativa (HS) and its scientific and clinical experience with its breakthrough anti-C5a monoclonal antibody IFX-1, on Friday, September 7 in New York City.

• 

  Germany-Based Companies Open Lab Space in U.S.

  6/6/2018

  There are several recent announcements of German companies opening laboratories in the U.S.

• InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

  3/8/2018

  InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced enrollment of the first patient in its Phase IIb study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS).

• InflaRx Presents at Two Scientific Conferences in February, 2018

  2/1/2018

  InflaRx N.V. will present data on IFX-1, an anti-C5a monoclonal antibody, at two international scientific conferences.

• InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

  1/9/2018

  The open IND will allow InflaRx to conduct a phase IIb study to determine efficacy and safety of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate or severe Hidradenitis Suppurativa.

• 

  German Biotech InflaRx Snags $100M in IPO

  11/9/2017

  The company announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share.

• InflaRx Scores $55 Million To Push Lead Drug Into Phase II Trials

  10/13/2017

• InflaRx Announces A $ 55M Series D Financing And Investment Round To Foster Its Clinical Stage Complement Anti-C5a Development Programs

  10/13/2017

• InflaRx Reports Topline Phase IIa Clinical Results Of IFX-1 For The Treatment Of Hidradenitis Suppurativa

  9/7/2017

• InflaRx Bags $34 Million Series C to Foster Complement Inhibitor Development

  7/21/2016

• InflaRx Announces Positive Phase IIa Top-Line Results From The SCIENS Trial Investigating IFX-1, A First-In-Class Anti-Complement C5a Antibody

  1/29/2016

• InflaRx Announces Successful Closing Of Its Round B Financing

  7/17/2014

• InflaRx Closes Funding to Move Its Complement Antibody Program into Clinical Trials for Sepsis Treatment

  3/18/2009

• InflaRx Raises Financing to Develop a New Therapeutic Approach Against Sepsis

  3/18/2008